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New drug development in cancer treatment leads to the
introduction of active agents rather infrequently, still less
often to the introduction ofcompletely new classes ofdrugs.
The development of analogues in the last decade has been
largely unrewarding, with little improvement in the outcome
ofchemotherapy for most solid tumours. Therefore our focus
should indeed be on discovery of drugs of novel structure
and/or mechanism of action. In the last few years, two new
classes of drugs have received increasing attention, although
their classification as 'new' is not completely correct. The first
taxoid and the first topoisomerase I inhibitor, pacitaxel and
camptothecin respectively, were both isolated some 20-30
years ago, interestingly enough by the same group of inves-
tigators. However, for different reasons their full clnical
development only recently matured.
This issue of the journal includes three reports on clinical
studies with the taxane drug docetaxel (Taxotere). At this
stage of clinical development, how can the relevance of this
drug be properly interpreted? The gold staaxlrd for further
development has always been that a new drug should have a
response rate of 15-20% in a properly designed phase H
study. Although this may still be true for a few chemo-
therapy-insensitive diseases such as malignant melanoma and
soft-tissue sarcomas, it is presumably an incorrect assump- tion for chemotherapy-sensitive diseases. In diseases such as
breast cancer we should set our standards higher. And even
in intermediately responsive diseases such as non-small-cell
lung cancer, drugs with a response rate of 15-20% have
hardly contributed to any survival improvement. Finally, the
design ofphase IIstudies should be taken into account when
analysing the data. The extensiveness of pretreatment should
be balanced against the likelihood of response in order to
avoid over- or underestimation of the true activity. The first
results with docetaxel should be analysed from this perspec- tive.
Docetaxel is the second representative of the new entity of
drugs that have a unique taxane ring in common. The parent taxooid drug paclitaxel (Taxol) (Wani et al., 1971) was
recently registered in the USA and some European countries
for the treatment of ovarian cancer. Paclitaxel is extracted
from a non-renewable source. Docetaxel was semisynthesised
in 1986 using a precursor extracted from the needles of the
European Yew Taxus baccata (Mangatal et al., 1989). Because of the regenerating capacity of the source this drug
is more readily available. In addition in vitro and in vivo data
have almost universally shown a greater potency ofdocetaxel
as compared with paclitaxel.
The mechanism of action of these drugs is unique. Both
taxanes bind preferentially and reversibly to the a-subunit of
tubulin in microtubules (Pazdur et al., 1993). This binding enhances tubulin polymerisation and inhibits microtubule
depolymerisation, thereby inducing the formation of stable
microtubule bundles. This disruption of the normal equili- brium ultimately leads to cell death.
In this issue Cerny et al. report a 23% response rate for
docetaxel in a multicentre, multinational study in 33
evaluable patients with stage III or IV non-chemotherapy- pretreated non-small-cell lung cancer. This is the first official
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report of a series of four similar studies involving in total
more than 100 patients, and showing an overall response rate
of 30%. The fact that four independent studies, one a multi-
centre study, all result in response rates higher than 20%
suggests that the true response may indeed be well over 20%.
Furthermore, it is certainly of interest that docetaxel retains
its activity in second-line chemotherapy (Burris et al., 1993)
in patients who generally will have an extremely poor prog-
nosis. In non-small-lung cancer only a few drugs have shown
some activity, and the debate on the impact of combination
chemotherapy on survival is still ongoing (Grilli et al., 1993;
Souquet et al., 1993). Some claim that survival with
chemotherapy is not superior to that obtained with best
supportive care, while others suggest a survival benefit for
combination chemotherapy. Even if a survival benefit truly
exists, it is certainly limited. To some extent this may be
related to limitations in dose intensity because ofoverlapping
toxicities of the drugs used in combination. Recent ongoing
studies have shown that relatively high doses of docetaxel
can be combined with standard doses of cisplatin, the stan-
dard drug used to treat non-small-cell lung cancer. In addi-
tion, the survival data presented by Cerny et al. appear
interesting, although it should be borne in mind this was only
a phase II study. Nevertheless, in view of these facts, studies
combining docetaxel with drugs such as isplatin deserve
priority in this disease.
The reported activity of docetaxel in prechnical studies
appears to be confirmed clinically in patients with gastric
cancer also. While paclitaxel at the high dose of 250 mg m-2
yielded a disappointing response rate of 5% in non-
pretreated patients (Finzig et al., 1993), Sulkes et al. in this
issue report a 24% response rate with docetaxel in 33
patients. Single-agent response rates of drugs considered
active vary from 20 to 30% in first-line treatment of gastric
cancer. In addition, a recently reported randomised study
suggested that survival after single-agent treatment with 5-
fluorouracil, a relatively inactive drug, is similar to survival
after combination chemotherapy, casting doubt on the value
ofpresently used combination chemotherapy regimens in this
disease (Cullinan et al., 1993). Whether this will change with
the incorporation of docetaxel into combination
chemotherapy is obviously not yet known. Nevertheless, the
reported single-agent activity of docetaxel should encourage
studies using this drug in combination with others.
Unfortunately, docetaxel is not active against colorectal
cancer, as reported by Stemnberg et al. in this issue.
What about other diseases? The results of many studies
using docetaxel in different tumour types have recently been
published elsewhere or will be published soon. From these
studies docetaxel emerges as an extremely active drug in the
treatment of breast cancer. In three independent studies (two
multicentre) first-line chemotherapy response rates varied
from 65 to 76% (Pazdur et al., 1993). This seems even better
than the results of recent studies with frequently used
combinations of drugs. Remarkably, the response rate in
second-line chemotherapy (62%) is only slightly lower than
in first-line chemotherapy, which again is an uncommon
observation. Such data have been unprecedented in this
disease and do justify a degree of enthusiasm. Very good
response rates have also been reported in ovarian cancer,
head and neck cancer, small-cell lung cancer, malignant
Br. J. Cancer (1994), 70, 183-184 C Macmifan Press Ltd., 1994184 J. VERWEIJ
melanoma. pancreatic cancer and soft-tissue sarcomas.
Beside the positive messaze of activity. the development of
docetaxel also has led to specific problems. particularly the
recoznition of some burdensome side-effects. In contrast to
paclitaxel. hypersensitivity reactions are less frequent and can
easilY be prevented by proper premedication. Some of the
side-effects of docetaxel. such as alopecia. frequent but most
often uncomplicated short-lasting neutropenia and less fre-
quent and usually mild nausea and or voomiting. diarrhoea
and mucositis. are not uncommon with other cytotoxic
drugs. Unusual side-effects include mild and easily treatable
arthralgia mval ia and skin toxicity and fluid retention (the
latter beinz related to the cumulative dose) which are much
more problematic. Most experience to date has been obtained
in patients who have not received routine premedication
treatment. as is usual with paclitaxel. Skin toxicity consists of
er-thema. desquamation and infrequent exfoliation and or
nail toxicity- consisting of discoloration and sometimes pain-
ful onvcholysis. Most frequently fluid retention consists of
peripheral edema. but pleural effusions and ascites have also
been reported. Data on how to manage or prevent these
side-effects are certainlv not conclusive. and studies on
various premedication regimens are ongoing. Of course. pac-
litaxel also has some side-effects. such as cardiotoxicitv and
neurotoxicity. which do not. however. appear to be a prob-
lem with docetaxel. However. it should not be forgotten that
the most active and frequently used drug in the treatment of
solid tumors. cisplatin. has major side-effects that incap-
acitated the first patients treated with this drug. Over the
y-ears we have learned how to deal with these side-effects. and
presently cisplatin is used in many non-specialised hospitals.
As lonz as studies on the pathogenesis of the side-effects
continue to be performed and the majority of patients treated
with docetaxel are treated in specialist centres and properly
monitored. there is a good chance that specific measures to
prevent nail toxicitx and fluid retention will be found. This
will enable prolonged treatment. which may be of relevance
for patients with metastatic disease. Short-lasting treatment
for 5-6 cycles already seems quite feAsible. Therefore. com-
bination chemotherapy regimens including docetaxel should
further be studied. In addition. docetaxel could become an
attractive option for studies on adjuvant chemotherapy in
breast cancer.
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